Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Context Modern management of differentiated thyroid cancer requires individualized care
plans that tailor the intensity of therapy and follow-up to the estimated risks of recurrence …

Abstract On September 17, 2021, the FDA approved cabozantinib (Cabometyx; Exelixis,
Inc.) for the treatment of adult and pediatric patients 12 years of age and older with locally …

Background: The 2015 American Thyroid Association (ATA) guidelines proposed a three-
category system for estimating the risk of recurrence of differentiated thyroid carcinoma …

Background: The 2015 American Thyroid Association (ATA) Risk Stratification System for
differentiated thyroid cancer (DTC) is designed to predict recurring/persisting disease but not …

The stratification of patients with differentiated thyroid cancer based on their initial risk of
recurrence, according to specific clinical, histopathological and perioperative data, is an …

Background Malignant struma ovarii (MSO) is a unique type of ovarian malignancy that data
on the survival outcome is limited and management strategy remains controversial due to its …

Background Comorbidity among cancer patients is prevalent and influential to prognosis
after operation. Limited data are available on comorbidity evaluations in patients with …

Abstract Context American Thyroid Association (ATA) guidelines do not consider age at
diagnosis as a prognostic factor on the estimation of the risk of persistent/recurrent disease …

目的: 探讨前列腺特异抗原(PSA) 灰区前列腺癌(PCa) 患者预后的独立预测因素,
并为其建立个体化预测的列线图模型. 方法: 回顾性检索2010—2016 年PCa 患者的临床资料 …